Leucegene data availability statement
Leucegene data availability statement The datasets generated by the Leucegene project are only partially accessible to the public due to legal and ethical limitations. We understand the importance of data […]
Author Archive for: muriel
Entries by Muriel Draoui
Leucegene data availability statement
Leucegene data availability statement The datasets generated by the Leucegene project are only partially accessible to the public due to legal and ethical limitations. We understand the importance of data […]
Listen to Guy Sauvageau’s interview at the ESH 5th International Conference on AML
Click on Guy Sauvageau’s interview last october on why should we target RUNX1 in AML treatment.
The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.
New publication in Blood
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations is now published in Blood.
Publication de l’équipe Leucegene dans Blood Cancer Journal
Maiga et al. a publié Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets dans la revue scientifique Blood Cancer Journal.
MiSTIC est maintenant publié dans la revue Nucleic Acids Research
Lemieux et al. a publié MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets dans la revue scientifique Nucleic Acids Research.